IR call - Acquisition of Bioverativ Inc.

Sanofi will acquire Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders.
Sanofi hosted a conference call & webcast on the acquisition for the financial community.

• Recorded audio webcast
• Call transcript
• Presentation
• Press release - January 22, 2018: Sanofi to Acquire Bioverativ for $11.6 Billion